Do analysts prefer CVAC or DNLI?

Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 32.60%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Denali Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.81

Do analysts recommend CVAC or NAMS?

NewAmsterdam Pharma has a consensus price target of $49.00, suggesting a potential upside of 40.68%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83

Which has preferable earnings and valuation, CVAC or NAMS?

CureVac has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 NewAmsterdam Pharma $22.50M 180.96 -$203.82M -$1.79 N/A

Do analysts recommend RCUS or CVAC?

Arcus Biosciences presently has a consensus target price of $35.10, indicating a potential upside of 15.38%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RCUS or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Arcus Biosciences' net margin of -156.36%. CureVac's return on equity of -23.03% beat Arcus Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Arcus Biosciences -156.36% -68.97% -35.27% CureVac 199.92% -23.03% -19.09%

Do analysts recommend TLX or CVAC?

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 77.97%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, TLX or CVAC?

CureVac has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 5.01 -$7.12M N/A N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 07/2/2026

Compare

CVAC vs. DNLI, NAMS, CRNX, RCUS, and TLX

Should you buy CureVac stock or one of its competitors? MarketBeat compares CureVac with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CureVac include Denali Therapeutics (DNLI), NewAmsterdam Pharma (NAMS), Crinetics Pharmaceuticals (CRNX), Arcus Biosciences (RCUS), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does CureVac compare to Denali Therapeutics?

CureVac (NASDAQ:CVAC) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 32.60%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81

17.3% of CureVac shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Denali Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Denali Therapeutics	N/A	-52.20%	-43.86%

In the previous week, Denali Therapeutics had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Denali Therapeutics and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 equaled Denali Therapeutics'average media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
Denali Therapeutics	Neutral

CureVac has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Denali Therapeutics	N/A	N/A	-$512.54M	-$2.88	N/A

Summary

CureVac beats Denali Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CureVac compare to NewAmsterdam Pharma?

CureVac (NASDAQ:CVAC) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, NewAmsterdam Pharma had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
NewAmsterdam Pharma	Neutral

NewAmsterdam Pharma has a consensus price target of $49.00, suggesting a potential upside of 40.68%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

CureVac has a net margin of 199.92% compared to NewAmsterdam Pharma's net margin of -943.23%. CureVac's return on equity of -23.03% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

CureVac has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
NewAmsterdam Pharma	$22.50M	180.96	-$203.82M	-$1.79	N/A

Summary

CureVac and NewAmsterdam Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Crinetics Pharmaceuticals presently has a consensus price target of $73.78, suggesting a potential upside of 74.70%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Crinetics Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Crinetics Pharmaceuticals had 7 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 0 mentions for CureVac. Crinetics Pharmaceuticals' average media sentiment score of 1.04 beat CureVac's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Positive
CureVac	Neutral

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Crinetics Pharmaceuticals has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

CureVac has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	578.28	-$465.32M	-$5.13	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. CureVac's return on equity of -23.03% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
CureVac	199.92%	-23.03%	-19.09%

Summary

Crinetics Pharmaceuticals beats CureVac on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

In the previous week, Arcus Biosciences had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Arcus Biosciences and 0 mentions for CureVac. Arcus Biosciences' average media sentiment score of 0.06 beat CureVac's score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Arcus Biosciences	Neutral
CureVac	Neutral

CureVac has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.49	-$353M	-$3.18	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Arcus Biosciences' net margin of -156.36%. CureVac's return on equity of -23.03% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
CureVac	199.92%	-23.03%	-19.09%

Arcus Biosciences presently has a consensus target price of $35.10, indicating a potential upside of 15.38%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Arcus Biosciences beats CureVac on 9 of the 16 factors compared between the two stocks.

How does CureVac compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Telix Pharmaceuticals has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Telix Pharmaceuticals' score of -0.32 indicating that CureVac is being referred to more favorably in the news media.

Company	Overall Sentiment
Telix Pharmaceuticals	Neutral
CureVac	Neutral

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 77.97%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CureVac has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	5.01	-$7.12M	N/A	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

17.3% of CureVac shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CureVac has a net margin of 199.92% compared to Telix Pharmaceuticals' net margin of 0.00%. Telix Pharmaceuticals' return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
CureVac	199.92%	-23.03%	-19.09%

Summary

Telix Pharmaceuticals beats CureVac on 8 of the 15 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05B	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	6.47	21.61	28.02	24.70
Price / Sales	14.78	343.35	538.99	99.06
Price / Cash	4.73	147.12	49.26	57.09
Price / Book	1.39	8.66	10.96	6.46
Net Income	$175.50M	$23.81M	$3.57B	$337.01M
7 Day Performance	N/A	3.39%	2.12%	1.69%
1 Month Performance	N/A	10.81%	5.25%	3.81%
1 Year Performance	-13.62%	62.61%	33.29%	23.90%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
DNLI Denali Therapeutics	2.5662 of 5 stars	$25.90 +0.1%	$34.25 +32.2%	+75.8%	$4.11B	$330.53M	N/A	430
NAMS NewAmsterdam Pharma	2.217 of 5 stars	$33.78 -0.3%	$48.60 +43.9%	+75.5%	$3.96B	$22.50M	N/A	4	Analyst Forecast Gap Up
CRNX Crinetics Pharmaceuticals	3.606 of 5 stars	$37.60 +1.8%	$76.13 +102.5%	+41.4%	$3.95B	$7.70M	N/A	210	Positive News Analyst Forecast Gap Down
RCUS Arcus Biosciences	2.1913 of 5 stars	$31.29 +0.7%	$35.10 +12.2%	+259.4%	$3.93B	$247M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. DNLI, NAMS, CRNX, RCUS, and TLX

How does CureVac compare to Denali Therapeutics?

Summary

How does CureVac compare to NewAmsterdam Pharma?

Summary

How does CureVac compare to Crinetics Pharmaceuticals?

Summary

How does CureVac compare to Arcus Biosciences?

Summary

How does CureVac compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. DNLI, NAMS, CRNX, RCUS, and TLX

How does CureVac compare to Denali Therapeutics?

Which has more volatility and risk, CVAC or DNLI?

Do analysts prefer CVAC or DNLI?

Do insiders & institutionals have more ownership in CVAC or DNLI?

Is CVAC or DNLI more profitable?

Does the media favor CVAC or DNLI?

Which has higher valuation and earnings, CVAC or DNLI?

Summary

How does CureVac compare to NewAmsterdam Pharma?

Which has more volatility and risk, CVAC or NAMS?

Do insiders and institutionals have more ownership in CVAC or NAMS?

Does the media favor CVAC or NAMS?

Do analysts recommend CVAC or NAMS?

Is CVAC or NAMS more profitable?

Which has preferable earnings and valuation, CVAC or NAMS?

Summary

How does CureVac compare to Crinetics Pharmaceuticals?

Do analysts prefer CRNX or CVAC?

Does the media favor CRNX or CVAC?

Do insiders and institutionals hold more shares of CRNX or CVAC?

Which has more risk and volatility, CRNX or CVAC?

Which has preferable earnings and valuation, CRNX or CVAC?

Is CRNX or CVAC more profitable?

Summary

How does CureVac compare to Arcus Biosciences?

Do insiders & institutionals have more ownership in RCUS or CVAC?

Which has more risk and volatility, RCUS or CVAC?

Does the media refer more to RCUS or CVAC?

Which has higher earnings & valuation, RCUS or CVAC?

Is RCUS or CVAC more profitable?

Do analysts recommend RCUS or CVAC?

Summary

How does CureVac compare to Telix Pharmaceuticals?

Which has more volatility and risk, TLX or CVAC?

Does the media refer more to TLX or CVAC?

Do analysts recommend TLX or CVAC?

Which has preferable valuation & earnings, TLX or CVAC?

Do insiders and institutionals have more ownership in TLX or CVAC?

Is TLX or CVAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools